Protagenic Therapeutics, Inc.
21.3.2024 13:43:15 CET | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This resolves the issue of potential delisting from Nasdaq by May 19, 2024 that the company had been facing.
On Tuesday, November 21, 2023, the company received a deficiency letter from Nasdaq stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, because it had not maintained a minimum bid price of $1.00 per share for 30 consecutive trading days. The Notification Letter stated that the company had 180 calendar days, or until May 19, 2024, to regain compliance by having a closing bid price of at least $1.00 per share for ten consecutive trading days. On March 19, 2024, the company received a formal notice from Nasdaq confirming that it has regained compliance with Listing Rule 5550(a)(2).
About Protagenic Therapeutics, Inc.:
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is committed to pioneering neuro-active peptides into therapeutics to mitigate stress-related disorders. For more information, visit www.protagenic.com.
About PT00114:
PT00114, a 41-amino-acid synthetic peptide, holds promise in treating various neuro-psychiatric conditions, including depression, anxiety, and PTSD. It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels.
Forward-Looking Statements:
This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.
Company Contact:
Alexander K. Arrow, MD, CFA Chief Financial Officer Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342 Email: alex.arrow@protagenic.com
Investor Relations Contact:
Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com
SOURCE: Protagenic Therapeutics, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform15.5.2026 22:55:00 CEST | Press release
NESHER, ISRAEL / ACCESS Newswire / May 15, 2026 / Tabor Electronics today announced the commercial release of its Anti-Drone Test and Evaluation (T&E) solution, introducing a software-defined approach to validating counter-unmanned aircraft systems (C-UAS). Built on the company's Proteus™ Software Defined Radio (SDR) platform, the solution enables defense and security organizations to test and deploy counter-drone technologies in rapidly changing threat environments. As low-cost drones proliferate and communication protocols evolve, traditional hardware-bound test environments are struggling to keep pace. Tabor's platform replaces these constraints with a programmable framework that allows engineering teams to emulate and validate real-world RF scenarios in controlled lab environments-reducing reliance on extended field testing while accelerating development timelines. Originally developed in collaboration with leading anti-drone technology companies, the solution has already been prov
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program14.5.2026 21:05:00 CEST | Press release
Highlights: WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutions Combination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmacies Proposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordination Proposed transaction valued at approximately $15 million Strategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providers TAMPA, FL / ACCESS Newswire / May 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million,
Karbon-X Explores Clean Cooking and Fish Smoking Climate Initiative Concept in Senegal14.5.2026 15:00:00 CEST | Press release
Concept contemplates future integration of digital monitoring technologies and community-focused climate infrastructure solutions. CALGARY, AB / ACCESS Newswire / May 14, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across compliance and voluntary carbon markets, today announced the exploration of a clean cooking and fish smoking climate initiative concept in Senegal focused on evaluating potential pathways for emissions reductions, improved fuel efficiency, and community-based climate infrastructure solutions. The initiative is currently at an early exploratory stage and is intended to assess opportunities associated with cleaner cooking technologies and, in later phases, more efficient fish smoking activities in rural communities. Traditional cooking and fish smoking practices continue to contribute to deforestation, indoor air pollution, and high fuel consumption across many regions. The concept contemp
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services13.5.2026 15:05:00 CEST | Press release
Highlights: According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹ Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructure Approximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providers Wellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiatives Participating pharmacists expected to gain access to new clinical service revenue opportunities TAMPA, FL / ACCESS Newswire / May 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution compa
The White House Names Peter Arnell as U.S. Chief Brand Architect within the National Design Studio13.5.2026 13:00:00 CEST | Press release
The White House today announced Peter Arnell as the first-ever Chief Brand Architect of the United States, a founding role within the National Design Studio. WASHINGTON, D.C. / ACCESS Newswire / May 13, 2026 / The White House today announced Peter Arnell as the first-ever Chief Brand Architect of the United States, a founding role within the National Design Studio. Arnell will serve as Chief Brand Architect to Joe Gebbia, U.S. Chief Design Officer, working in direct partnership to accelerate the President's Executive Order 14338: "Improving Our Nation Through Better Design". Widely regarded as one of the world's foremost brand architects, Arnell brings 45 years of experience creating and transforming global brands, corporations, and institutions across technology, automotive, healthcare, consumer products, fashion, and sports, as well as major public and nonprofit organizations including the Special Olympics and the FDNY Foundation. As Chief Brand Architect for the nation, Arnell will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom